🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — off 2 antihypertensives Page 2

My blood pressure normalization journey — off 2 antihypertensives

BethLabQueen Sat, May 16, 2026 at 5:28 PM 27 replies 640 viewsPage 2 of 6
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
May 18, 2026 at 3:19 AM#6
LibrarianMeg said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

46 16Dr.LeslieOBGYN, MikeNYC_runner and 43 others
Reply Quote Save Share Report
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
May 18, 2026 at 4:50 PM#7
BethLabQueen said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
Last edited: May 18, 2026 at 8:50 PM
45 15tom_AK, josh_phd_bmore, roxy_nash and 42 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
May 19, 2026 at 6:21 AM#8
PurityPaulOR said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

Last edited: May 19, 2026 at 11:21 AM
44 14ingrid_STO, pete_nash, hank_denver and 41 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
paul_denver
Member
723
3,234
May 2024
Denver, CO
May 19, 2026 at 7:52 PM#9

One thing that is still open after PedsEndoPhilly’s answer:

What did you change at the same time, and can you separate the two now?

43 13sarah_TO, wendy_avl, jason_paloalto and 40 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
May 22, 2026 at 12:41 PM#10
NurseKim_ATL said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

6 month update on cardiovascular risk: down 58 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

3 3wei_SG, cory_ATX, lori_vegas
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register